|Title:||Co-Founder and Vice President|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||SiMPore is a seed-stage company commercializing a breakthrough technology for the separation and purification of biomolecules and other nano-sized particles. SiMPore’s porous nanocrystalline silicon membrane (pnc-Si) has attracted considerable worldwide attention following the recent report of its discovery in the journal Nature.
Current membrane technologies are far from ideal because they non-specifically trap and bind molecules, cannot separate molecules of similar size, and do not permit recovery of molecules passed through the membrane. As a result, there is a large demand for new membrane technologies that overcome these problems.
The extreme thinness and robust nature of SiMPore’s proprietary pnc-Si membrane material overcomes these limitations, enabling the highest filtration efficiency of any molecular-scale membrane-filter. It is the first and only membrane that allows separation and recovery of closely sized molecules and wafer-level manufacturing is scalable and readily customized.
SiMPore intends to capture the value of this technology through a combination of direct sales and licensing diverse products for multiple markets, including laboratory filtration ($500 million) and biomanufacturing filtration ($1.3 billion). Application of SiMPore’s technology in these markets will revolutionize the methods by which critical biomolecules are separated and purified.|
|Venture is:||Seed Level|